Form 4: Septerna Director Jeffrey Tong Granted 16,623 Stock Options at $10.24 Exercise Price

Septerna, Inc. Director and 10% Owner Jeffrey K. Tong was granted 16,623 stock options with an exercise price of $10.24 per share, vesting upon continued service.

Summary

• Jeffrey K. Tong, a Director and 10% Owner of Septerna, Inc. (SEPN), was granted 16,623 stock options.
• The transaction date for this acquisition was June 17, 2025.
• Each stock option has an exercise price of $10.24.
• The options represent the right to buy 16,623 shares of Septerna's common stock.
• These options will vest in full upon the earlier of June 17, 2026, or the Issuer's next annual meeting of stockholders, contingent on Mr. Tong's continued service to the company.
• The expiration date for these stock options is June 16, 2035.
• Following this transaction, Mr. Tong beneficially owns 16,623 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally viewed as a neutral to slightly positive event, as it aligns the director's interests with shareholders and incentivizes long-term performance. It is a routine compensation disclosure.

Positives

• The grant of stock options to a director aligns their interests with shareholders, as the options gain value if the stock price increases.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the stock options is dependent on the future performance of Septerna, Inc.'s common stock. If the stock price does not exceed the exercise price of $10.24, the options may expire worthless.
• Vesting is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continued service from Director Jeffrey K. Tong until at least June 17, 2026, or the company's next annual meeting of stockholders, aligning his incentives with the company's long-term performance.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common across all industries, including the biotechnology or pharmaceutical sector where Septerna, Inc. likely operates. Such grants are standard practice for executive and director compensation, aiming to align their interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a common compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize long-term performance and retention.
• The exercise price being set at the market price on the grant date (implied by the $0 price in column 8 and the exercise price in column 2) is standard for incentive stock options.
• The vesting period (up to one year or next annual meeting) is a typical short-to-medium term vesting schedule for director grants, designed to retain talent and align interests. Specific comparable companies or projects are not mentioned in the document, so a detailed comparison is not possible from this filing alone.

Stakeholder Impact

• Shareholders: May view the option grant as a positive signal of management's alignment with shareholder interests and confidence in future stock performance. It is a standard component of director compensation.

Next Steps

• The stock options will vest upon the earlier of June 17, 2026, or Septerna's next annual meeting of stockholders, subject to continued service.
• Jeffrey K. Tong may choose to exercise the options at any time after vesting and before the expiration date of June 16, 2035.

Key Dates

Keywords

Septerna, SEPN, Form 4, insider transaction, stock option, director compensation, beneficial ownership, equity grant, Jeffrey K. Tong